1
40
1
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
February 2020 List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
February 2020 List
URL Address
<a href="http://doi.org/10.1016/j.seizure.2019.12.006" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.seizure.2019.12.006</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cannabis-based products for pediatric epilepsy: An updated systematic review
Publisher
An entity responsible for making the resource available
Seizure
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
Subject
The topic of the resource
Cannabidiol; Efficacy; Living systematic review; Paediatric drug-resistant epilepsy; Safety; Seizure
Creator
An entity primarily responsible for making the resource
Elliott J; DeJean D; Clifford T; Coyle D; Potter B K; Skidmore B; Alexander C; Repetski A E; Shukla V; McCoy B; Wells G A
Description
An account of the resource
PURPOSE: To provide an up-to-date summary of the benefits and harms of cannabis-based products for epilepsy in children. METHODS: We updated our earlier systematic review, by searching for studies published up to May 2019. We included randomized controlled trials (RCTs) and non-randomized studies (NRS) involving cannabis-based products administered to children with epilepsy. Outcomes were seizure freedom, seizure frequency, quality of life, sleep, status epilepticus, death, gastrointestinal adverse events, and emergency room visits. RESULTS: Thirty-five studies, including four RCTs, have assessed the benefits and harms of cannabis-based products in pediatric epilepsy (12 since April 2018). All involved cannabis-based products as adjunctive treatment, and most involved cannabidiol. In the RCTs, there was no statistically significant difference between cannabidiol and placebo for seizure freedom (relative risk 6.77, 95 % confidence interval [CI] 0.36-128.38), quality of life (mean difference [MD] 0.6, 95 %CI -2.6 to 3.9), or sleep disruption (MD -0.3, 95 %CI -0.8 to 0.2). Data from both RCTs and NRS suggest that cannabidiol reduces seizure frequency and increases treatment response; however, there is an increased risk of gastrointestinal adverse events. CONCLUSION: Newly available evidence supports earlier findings that cannabidiol probably reduces the frequency of seizures among children with drug-resistant epilepsy. PROSPERO: CRD42018084755.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.seizure.2019.12.006" target="_blank" rel="noreferrer noopener">10.1016/j.seizure.2019.12.006</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2019
Alexander C
Cannabidiol
Clifford T
Coyle D
DeJean D
Efficacy
Elliott J
February 2020 List
Living systematic review
McCoy B
Paediatric drug-resistant epilepsy
Potter B K
Repetski A E
Safety
Seizure
Shukla V
Skidmore B
Wells G A